Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation

被引:14
|
作者
Tamplen, Matthew [1 ]
Fowler, Tristan [2 ]
Markey, Jeffery [1 ]
Knott, P. Daniel [1 ]
Suva, Larry J. [3 ]
Alliston, Tamara [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94104 USA
[2] Univ Calif San Francisco, Dept Orthoped Surg, San Francisco, CA 94104 USA
[3] Texas A&M Univ, Dept Vet Physiol, College Stn, TX USA
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2018年 / 40卷 / 07期
基金
美国国家卫生研究院;
关键词
head and neck reconstruction; mandible; micro-CT; osteoradionecrosis; sclerostin; DOWN-SYNDROME; RAT MODEL; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; GENE; OSTEORADIONECROSIS; OSTEONECROSIS; OSTEOPOROSIS; MASS; PERIODONTITIS;
D O I
10.1002/hed.25128
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: Anti-Sclerostin antibody (Scl-Ab) is a promising new bone anabolic therapy. Although anti-Scl-Ab stimulates bone formation and repair in the appendicular and axial skeleton, its efficacy in the craniofacial skeleton is still poorly understood. Methods: Using an established model of Down syndrome-dependent bone deficiency, 10 Ts65Dn mice and 10 wild-type mice were treated weekly via i.v. tail vein injection with vehicle or anti-Sclerostin for 3 weeks and euthanized 1 week after. Results: Wild-type mice treated with the anti-Scl-Ab had increased mandibular bone, trabecular thickness, and alveolar height compared with controls. Anti-Scl-Ab increased Ts65Dn mandibular bone parameters such that they were statistically indistinguishable from those in vehicle-treated wild-type mandibles. Conclusion: Treatment with anti-Scl-Ab significantly increased mandibular bone mass and alveolar height in wild type mice and normalized mandibular bone mass and alveolar height in Ts65Dn mice. The anti-Scl-Ab therapy represents a novel method for increasing mandibular bone formation.
引用
收藏
页码:1453 / 1460
页数:8
相关论文
共 50 条
  • [31] Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse
    Sun, Weiwei
    Shi, Yu
    Lee, Wen-Chih
    Lee, Seung-Yon
    Long, Fanxin
    BONE, 2016, 85 : 1 - 8
  • [32] NOVEL TREATMENTS: ODANACATIB AND ANTI-SCLEROSTIN ANTIBODIES
    Seeman, E.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S694 - S695
  • [33] BPS804, an anti-sclerostin monoclonal antibody, improves disease biomarkers and markers of bone formation in patients with adult-onset hypophosphatasia (HPP)
    Seefried, Lothar
    Baumann, Jasmin
    Hemsley, Sarah
    Hu, Shou-Ih
    Halleux, Christine
    Kiese, Beate
    Huang, Yue
    Golieb, Steven
    Chivers, Simon
    Valentin, Marie-Anne
    Borah, Babul
    Kneissel, Michaela
    Jakob, Franz
    Junker, Uwe
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [34] Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia
    Seefried, Lothar
    Baumann, Jasmin
    Hemsley, Sarah
    Hofmann, Christine
    Kunstmann, Erdmute
    Kiese, Beate
    Huang, Yue
    Chivers, Simon
    Valentin, Marie-Anne
    Borah, Babul
    Roubenoff, Ronenn
    Junker, Uwe
    Jakob, Franz
    JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (06): : 2148 - 2158
  • [35] Affinity-targeting of Anti-sclerostin Antibody to the Bone Surface Significantly Increases Therapeutic Efficacy in an Ovariectomy Mouse Model of Osteoporosis
    Zhang, Boya
    Swanson, Ben
    Durden, Margaret
    Weivoda, Megan
    Mishina, Yuji
    Greineder, Colin
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 368 - 368
  • [36] Osteoporosis Treatment with Anti-Sclerostin Antibodies-Mechanisms of Action and Clinical Application
    Rauner, Martina
    Taipaleenmaeki, Hanna
    Tsourdi, Elena
    Winter, Elizabeth M.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 21
  • [37] Bone CLARITY reveals that anti-sclerostin antibody penetrates the lacunar canalicular system in mice under physiological loading conditions.
    Greenbaum, Alon
    Chan, Ken
    Boyce, Rogely
    Salimi-Moosavi, Hossein
    McBride, Helen J.
    Gradinaru, Viviana
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S293 - S293
  • [38] Anti-sclerostin Antibodies for the Treatment of Osteoporosis: A Systematic Review and Meta-analysis
    Pundole, Xerxes
    Lopez-Olivo, Maria
    Suarez-Almazor, Maria
    Lu, Huifang
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 411 - 412
  • [39] Anti-sclerostin antibody therapy prevents post-ischemic osteonecrosis bone collapse via interleukin-6 association
    Ozawa, Yuto
    Takegami, Yasuhiko
    Osawa, Yusuke
    Asamoto, Takamune
    Tanaka, Shinya
    Imagama, Shiro
    BONE, 2024, 181
  • [40] Pretreatment with Anti-Sclerostin Antibody has Lasting Osteogenic Effects on the Femur of Unloaded Male Rats
    Elizondo, Jon
    Lenfest, Scott
    Sihra, Sandhya
    Kosniewski, Jennifer
    Black, Jeremy
    Kohn, Zachary
    Brezicha, Jessica
    Bloomfield, Susan
    Hogan, Harry
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 65 - 66